Allos Therapeutics to Present at the RBC Capital Markets 2008 Healthcare Conference
09 Décembre 2008 - 10:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer, today announced that
members of the Company�s senior management will participate in a
panel presentation, �Waging a Battle Against Cancer,� at the RBC
Capital Markets 2008 Healthcare Conference. The panel presentation
will take place at 8:00 a.m. (Eastern) on Tuesday, December 11,
2008. There will be a live webcast of the presentation, which will
be accessible through a link posted on the Allos website home page
and investor relations section. The webcast will be available for
replay on Allos� website through December 26, 2008. About Allos
Therapeutics, Inc. Allos Therapeutics is a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer.�The Company's lead
product candidate, pralatrexate (PDX), is a novel antifolate
currently under evaluation in a pivotal Phase 2 (PROPEL) trial in
patients with relapsed or refractory peripheral T-cell lymphoma.
The Company reported top line results from PROPEL in December 2008.
Following review of the final results of the trial, the Company
intends to submit a New Drug Application (NDA) for pralatrexate for
the treatment of patients with relapsed or refractory PTCL in the
first half of 2009. The PROPEL trial is being conducted under an
agreement reached with the U.S. Food and Drug Administration under
its special protocol assessment (SPA) process. The Company is also
investigating pralatrexate in patients with non-small cell lung
cancer, bladder cancer and a range of lymphoma sub-types.�The
Company's other product candidate�is RH1, a targeted
chemotherapeutic agent currently being evaluated in a Phase 1 trial
in patients with advanced solid tumors or non-Hodgkin�s lymphoma
(NHL). The Company currently retains exclusive worldwide rights to
pralatrexate and RH1 for all indications. For additional
information, please visit the Company�s website at www.allos.com.
Safe Harbor Statement The anticipated presentation will contain
forward-looking statements that involve significant risks and
uncertainties. Additional information concerning these
forward-looking statements and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2007 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation. All
forward-looking statements are based on information currently
available to the Company on the date thereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics, Inc.